Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo
Microvesicles shed from cells carry constituents of the cell cytoplasm, including, of importance in multidrug resistance to cancer chemotherapy, drugs that the tumor cell attempts to efflux. To see whether such drugs could be used at lower concentrations with the same efficacy, it was first shown th...
Main Authors: | Jorfi, Samireh, Ansa-Addo, Ephraim A., Kholia, Sharad, Stratton, Dan, Valley, Shaunelle, Lange, Sigrun, Inal, Jameel |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548233/ |
Similar Items
-
A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy
by: Kholia, Sharad, et al.
Published: (2015) -
GP96: safeguarding Treg
by: Zhang, Yongliang, et al.
Published: (2015) -
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
by: Heinemann, Lucy, et al.
Published: (2011) -
Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
by: Jabir, Rafid, et al.
Published: (2014) -
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
by: Hilkens, P. H., et al.
Published: (1997)